Zogenix, Battelle agree to work toward out-licensing needle-free injection platform
This article was originally published in Scrip
Executive Summary
Zogenix has signed a letter of intent with Battelle, the research and development organisation, for a collaboration aimed at developing and commercialising Zogenix’ needle-free DosePro drug delivery technology in fields outside the firm’s core therapeutic areas which consist of CNS disorders and pain. The other uses could potentially be for delivery of high-dose biologics, which are either pipeline products or currently marketed products. For currently marketed drugs, the technology could form part of a life cycle management strategy.